Our ADP-A2M10 (MAGE-A10) T-cell therapy is directed to a highly immunogenic member of the MAGE family of cancer testis antigens expressed in a number of solid tumor cell types. Any expression in cancer is often associated with higher grade tumors.
Based on our ongoing preclinical evaluation, we believe our ADP-A2M10 T-cell therapeutic candidate has the potential ability to bind target peptides from multiple cancer types. We have two ongoing clinical trials to evaluate the safety and anti- tumor activity of ADP-A2M10: one with non-small cell lung cancer, and one with bladder, melanoma and head and neck cancers.
Please note that the two trials with ADP-A2M10 will be closed for enrollment by end of 2019.